Spero Therapeutics Inc
NASDAQ:SPRO
Spero Therapeutics Inc
Pre-Tax Income
Spero Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Spero Therapeutics Inc
NASDAQ:SPRO
|
Pre-Tax Income
$25.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Spero Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
25.4m
USD
Based on the financial report for Dec 31, 2023, Spero Therapeutics Inc's Pre-Tax Income amounts to 25.4m USD.